Peptides DB
Research-centric peptide and protocol reference hub
Study 4 of 10Triptorelin literaturebiorxiv-preprint · Observational2025

Perceived Stress During Gender-Affirming Hormone Therapy: A Comparative Study of Feminizing and Masculinizing Hormone Therapy in an International Multicenter Prospective Cohort

This study found no significant changes in perceived stress levels after 3 or 12 months of gender-affirming hormone therapy, indicating that improvements in well-being may not reduce stress.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the triptorelin corpus
0
Preclinical
8
Observational · this one
0
Open-label
1
Randomised
1
Reviews

Summary and findings

This study examined perceived stress levels in individuals undergoing gender-affirming hormone therapy (GAHT) over 3 and 12 months. A total of 442 participants completed the Perceived Stress Scale (PSS) before and after treatment. No significant changes in perceived stress were observed after GAHT.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
No significant changes in perceived stress were observed after 3 months (-1.0, p = 0.21).2025

Abstract

The authors’ words, as biorxiv-preprint supplied them

Cisgender women report higher stress than cisgender men, potentially due to psychosocial and biological factors, including sex hormone levels. Gender-affirming hormone therapy (GAHT) alters hormone levels, but its impact on perceived stress remains unclear. This study examined changes in perceived stress after 3 and 12 months of GAHT and potential differences between feminizing (FHT) and masculinizing hormone therapy (MHT). Data were drawn from two prospective cohort studies (ENIGI and RESTED) in the Netherlands, Belgium, and Israel. A total of 442 individuals (median age 23 years, IQR 20.5 to 28.0) completed the 10-item Perceived Stress Scale (PSS) before starting GAHT and after 3 and 12 months. Linear mixed models assessed changes after starting GAHT and differences between FHT and MHT groups. Baseline perceived stress levels did not significantly differ between groups (0.15, p = 0.84). No significant changes in perceived stress were observed after 3 or 12 months, nor were there significant differences in changes between FHT and MHT (-1.0, p = 0.21; 0.25, p = 0.76). Improvements in well-being during GAHT may not reduce perceived stress, potentially due to ongoing gender minority stressors. Future research should explore stressors and coping mechanisms to identify strategies for reducing perceived stress during GAHT.

Elsewhere in the Triptorelin corpus

AComparative effectiveness of luteal phase support strategies in natural cycle frozen-thawed embryo transfer: a systematic review and network meta-analysis.European journal of obstetrics, gynecology, and reproductive biology · 2026 · Not reported in abstract.reviewCProposed Method for Mass Spectrometric Measurement of the Gonadotropin-Releasing Hormone Agonist Deslorelin.Toxics · 2026 · Detectability optimized to <1 ppb.AnimalBComparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.Urologic oncology · 2026 · n=6666 · HR for MACE with LHRH-AG vs LHRH-AN was 0.86, 95% CI: 0.79-0.93.HumanAEvaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.BJU international · 2026 · n=88 · Not reported in abstract.HumanBOptimizing ovarian stimulation in oocyte donation: exploratory comparison of rhFSH (2:1) versus hp-hMG under PPOS protocols.JBRA assisted reproduction · 2023 · n=36 · Mean number of good-morphology blastocysts per cycle was 4.5 with rhFSH:rhLH vs 2.0 with hp-hMG.HumanBTreatment Outcomes in 84 Male Children with Accelerated Pubertal Progression: A Comparative Analysis ofGnRHa, Combined GH Therapy and Aromatase Inhibitorbiorxiv-preprint · 2026 · ΔH/y of combination therapy was 8.49 ± 3.22 cm/y, GnRHa was 6.73 ± 1.95 cm/y, and AI was 7.75 ± 1.92 cm/y, P < 0.01.Human